|
1
|
Cindolo L, Alvarez-Maestro M, Castellucci
R and Schips L: Efficacy and safety of dutasteride for the
treatment of symptomatic benign prostatic hyperplasia (BPH): A
systematic review and meta-analysis. World J Urol. 33:441–442.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kaplan SA: Re: Influence of immune
inflammation on androgen receptor expression in benign prostatic
hyperplasia tissue. J Urol. 189:10022013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gacci M, Salvi M, Sebastianelli A,
Vignozzi L, Corona G, McVary KT, Kaplan SA, Maggi M, Carini M and
Oelke M: The use of a single daily dose of tadalafil to treat signs
and symptoms of benign prostatic hyperplasia and erectile
dysfunction. Res Rep Urol. 5:99–111. 2013.PubMed/NCBI
|
|
4
|
Gao YA, Huang Y, Zhang R, Yang YD, Zhang
Q, Hou M and Wang Y: Benign prostatic hyperplasia: Prostatic
arterial embolization versus transurethral resection of the
prostate-a prospective, randomized and controlled clinical trial.
Radiology. 270:920–928. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cochetti G, Poli G, Guelfi G, Boni A,
Egidi MG and Mearini E: Different levels of serum microRNAs in
prostate cancer and benign prostatic hyperplasia: Evaluation of
potential diagnostic and prognostic role. Onco Targets Ther.
9:7545–7553. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tang B, Li N, Gu J, Zhuang Y, Li Q, Wang
HG, Fang Y, Yu B, Zhang JY, Xie QH, et al: Compromised autophagy by
MIR30B benefits the intracellular survival of Helicobacter pylori.
Autophagy. 8:1045–1057. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Andersen GB, Knudsen A, Hager H, Hansen LL
and Tost J: miRNA profiling identifies deregulated miRNAs
associated with osteosarcoma development and time to metastasis in
two large cohorts. Mol Oncol. Nov 9–2017.(Epub ahead of print).
|
|
8
|
Elliott KJ, Bourne AM, Takayanagi T,
Takaguri A, Kobayashi T, Eguchi K and Eguchi S: ADAM17 silencing by
adenovirus encoding miRNA-embedded siRNA revealed essential signal
transduction by angiotensin II in vascular smooth muscle cells. J
Mol Cell Cardiol. 62:1–7. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bordinhao AL, Evangelista AF, Oliveira RJ,
Macedo T, Silveira HC, Reis RM and Marques MM: MicroRNA profiling
in human breast cancer cell lines exposed to the anti-neoplastic
drug cediranib. Oncol Rep. 36:3197–3206. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chen P, Zhao H, Huang J, Yan X, Zhang Y
and Gao Y: MicroRNA-17-5p promotes gastric cancer proliferation,
migration and invasion by directly targeting early growth response
2. Am J Cancer Res. 6:2010–2020. 2016.PubMed/NCBI
|
|
11
|
Fu Y and Cao F: MicroRNA-125a-5p regulates
cancer cell proliferation and migration through NAIF1 in prostate
carcinoma. Onco Targets Ther. 8:3827–3835. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chen WY, Liu SY, Chang YS, Yin JJ, Yeh HL,
Mouhieddine TH, Hadadeh O, Abou-Kheir W and Liu YN: MicroRNA-34a
regulates WNT/TCF7 signaling and inhibits bone metastasis in
Ras-activated prostate cancer. Oncotarget. 6:441–457.
2015.PubMed/NCBI
|
|
13
|
Katz B, Reis ST, Viana NI, Morais DR,
Moura CM, Dip N, Silva IA, Iscaife A, Srougi M and Leite KR:
Comprehensive study of gene and microRNA expression related to
epithelial-mesenchymal transition in prostate cancer. PLoS One.
9:e1137002014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Viana NI, Reis ST, Dip NG, Morais DR,
Moura CM, Silva IA, Katz B, Srougi M, Leite KR and Antunes AA:
MicroRNAs 143 and 145 may be involved in benign prostatic
hyperplasia pathogenesis through regulation of target genes and
proteins. Int J Biol Markers. 29:e246–252. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Haj-Ahmad TA, Abdalla MA and Haj-Ahmad Y:
Potential urinary miRNA biomarker candidates for the accurate
detection of prostate cancer among benign prostatic hyperplasia
patients. J Cancer. 5:182–191. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang N, Ji N, Jiang WM, Li ZY, Wang M,
Wen JM, Li Y, Chen X and Chen JM: Hypoxia-induced autophagy
promotes human prostate stromal cells survival and ER-stress.
Biochem Biophys Res Commun. 464:1107–1112. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wu D and Gantier MP: Normalization of
Affymetrix miRNA microarrays for the analysis of cancer samples.
Methods Mol Biol. 1375:1–10. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Feber A, Xi L, Pennathur A, Gooding WE,
Bandla S, Wu M, Luketich JD, Godfrey TE and Litle VR: MicroRNA
prognostic signature for nodal metastases and survival in
esophageal adenocarcinoma. Ann Thorac Surg. 91:1523–1530. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Smeets A, Daemen A, Vanden Bempt I,
Gevaert O, Claes B, Wildiers H, Drijkoningen R, Van Hummelen P,
Lambrechts D, De Moor B, et al: Prediction of lymph node
involvement in breast cancer from primary tumor tissue using gene
expression profiling and miRNAs. Breast Cancer Res Treat.
129:767–776. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gao F, Nan F, Feng J, Lv J, Liu Q and Xie
S: Identification and characterization of microRNAs in Eucheuma
denticulatum by high-throughput sequencing and bioinformatics
analysis. RNA Biol. 13:343–352. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hayashi K, Chuva de Sousa Lopes SM, Kaneda
M, Tang F, Hajkova P, Lao K, O'Carroll D, Das PP, Tarakhovsky A,
Miska EA and Surani MA: MicroRNA biogenesis is required for mouse
primordial germ cell development and spermatogenesis. PLoS One.
3:e17382008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang C: MicroRNomics: A newly emerging
approach for disease biology. Physiol Genomics. 33:139–147. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Su J, Liang H, Yao W, Wang N, Zhang S, Yan
X, Feng H, Pang W, Wang Y, Wang X, et al: MiR-143 and MiR-145
regulate IGF1R to suppress cell proliferation in colorectal cancer.
PLoS One. 9:e1144202014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Xu YF, Li YQ, Guo R, He QM, Ren XY, Tang
XR, Jia WH, Kang TB, Zeng MS, Sun Y, et al: Identification of
miR-143 as a tumour suppressor in nasopharyngeal carcinoma based on
microRNA expression profiling. Int J Biochem Cell Biol. 61:120–128.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang GJ, Li JS, Zhou H, Xiao HX, Li Y and
Zhou T: MicroRNA-106b promotes colorectal cancer cell migration and
invasion by directly targeting DLC1. J Exp Clin Cancer Res.
34:732015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Huang P, Ye B, Yang Y, Shi J and Zhao H:
MicroRNA-181 functions as a tumor suppressor in non-small cell lung
cancer (NSCLC) by targeting Bcl-2. Tumour Biol. 36:3381–3387. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Khan K, Cunningham D, Peckitt C, Barton S,
Tait D, Hawkins M, Watkins D, Starling N, Rao S, Begum R, et al:
miR-21 expression and clinical outcome in locally advanced
pancreatic cancer: Exploratory analysis of the pancreatic cancer
Erbitux, radiotherapy and UFT (PERU) trial. Oncotarget.
7:12672–12681. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cheng CW, Wang HW, Chang CW, Chu HW, Chen
CY, Yu JC, Chao JI, Liu HF, Ding SL and Shen CY: MicroRNA-30a
inhibits cell migration and invasion by downregulating vimentin
expression and is a potential prognostic marker in breast cancer.
Breast Cancer Res Treat. 134:1081–1093. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Haflidadottir BS, Larne O, Martin M,
Persson M, Edsjö A, Bjartell A and Ceder Y: Upregulation of miR-96
enhances cellular proliferation of prostate cancer cells through
FOXO1. PLoS One. 8:e724002013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ress AL, Stiegelbauer V, Winter E,
Schwarzenbacher D, Kiesslich T, Lax S, Jahn S, Deutsch A,
Bauernhofer T, Ling H, et al: MiR-96-5p influences cellular growth
and is associated with poor survival in colorectal cancer patients.
Mol Carcinog. 54:1442–1450. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
32
|
Fendler A, Jung M, Stephan C, Erbersdobler
A, Jung K and Yousef GM: The antiapoptotic function of miR-96 in
prostate cancer by inhibition of FOXO1. PLoS One. 8:e808072013.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Assal RA, El Tayebi HM, Hosny KA, Esmat G
and Abdelaziz AI: A pleiotropic effect of the single clustered
hepatic metastamiRs miR-96-5p and miR-182-5p on insulin-like growth
factor II, insulin-like growth factor-1 receptor and insulin-like
growth factor-binding protein-3 in hepatocellular carcinoma. Mol
Med Rep. 12:645–650. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Vishwamitra D, Li Y, Wilson D, Manshouri
R, Curry CV, Shi B, Tang XM, Sheehan AM, Wistuba II, Shi P and Amin
HM: MicroRNA 96 is a post-transcriptional suppressor of anaplastic
lymphoma kinase expression. Am J Pathol. 180:1772–1780. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wu Z, Liu K, Wang Y, Xu Z, Meng J and Gu
S: Upregulation of microRNA-96 and its oncogenic functions by
targeting CDKN1A in bladder cancer. Cancer Cell Int. 15:1072015.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yu S, Lu Z, Liu C, Meng Y, Ma Y, Zhao W,
Liu J, Yu J and Chen J: miRNA-96 suppresses KRAS and functions as a
tumor suppressor gene in pancreatic cancer. Cancer Res.
70:6015–6025. 2010. View Article : Google Scholar : PubMed/NCBI
|
